How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Shares of Sun Pharmaceutical Industries Ltd. 524715 inched down 0.31% to 1,803.25 Indian rupees Tuesday, on what proved to be ...

Sun Pharma: The US District Court of New Jersey has issued a preliminary injunction blocking Sun Pharma from introducing the ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

According to Citi, the delay in the launch of Sun Pharma's alopecia areata drug, Leqselvi, could impact its near-term ...

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Pharma giant, Sun Pharmaceutical's launch of its specialty drug Leqselvi in the U.S. market is in limbo as the U.S. District Court in New Jersey has issued a preliminary injunction.

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

The U.S. District Court of New Jersey has issued a preliminary injunction preventing Sun Pharma from launching Leqselvi, a ...

Shares of Sun Pharmaceutical fell 2.64 per cent after the pharma major recently announced that the US District Court of delayed the launch of its new drug - Leqselvi.

After a US Court blocked the launch of Leqselvi, a drug used to treat severe alopecia areata, shares of Sun Pharma plunged ...